[Initial evaluation, diagnosis, staging, treatment, and follow-up of patients with primary cutaneous malignant melanoma. Consensus statement of the Network of Catalan and Balearic Melanoma Centers].
The consensus statement on the management of primary cutaneous melanoma that we present here was based on selection, discussion, review, and comparison of recent literature (including national and international guidelines). The protocols for the diagnosis, treatment, and follow-up used in the hospital centers throughout Catalonia and the Balearic Isles belonging to the Network of Catalan and Balearic Melanoma Centers were also considered. The main objective of this statement was to present the overall management of melanoma patients typically used in our region at the present time. As such, the statement was not designed to be an obligatory protocol for health professionals caring for this group of patients, and neither can it nor should it be used for this purpose. Professionals reading the statement should not therefore consider it binding on their practice, and in no case can this text be used to guarantee or seek responsibility for a given medical opinion. The group of dermatologists who have signed this statement was created 3 years ago with the aim of making our authorities aware of the importance of this complex tumor, which, in comparison with other types of cancer, we believe does not receive sufficient attention in Spain. In addition, the regular meetings of the group have produced interesting proposals for collaboration in various epidemiological, clinical, and basic applied research projects on the subject of malignant melanoma in our society.
Mangas
C
C
Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. cris_mangas@yahoo.es
Paradelo
C
C
Puig
S
S
Gallardo
F
F
Marcoval
J
J
Azon
A
A
Bartralot
R
R
Bel
S
S
Bigatà
X
X
Curcó
N
N
Dalmau
J
J
del Pozo
L J
LJ
Ferrándiz
C
C
Formigón
M
M
González
A
A
Just
M
M
Llambrich
A
A
Llistosella
E
E
Malvehy
J
J
Martí
R M
RM
Nogués
M E
ME
Pedragosa
R
R
Rocamora
V
V
Sàbat
M
M
Salleras
M
M
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001706:Biopsy; D019496:Cancer Vaccines / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000175:diagnosis / Q000473:pathology / Q000556:secondary / Q000628:therapy; D008875:Middle Aged; D009367:Neoplasm Staging; D010166:Palliative Care; D010346:Patient Care Management; D010808:Physical Examination; D018714:Radiotherapy, Adjuvant; D012042:Registries; D021701:Sentinel Lymph Node Biopsy; D012878:Skin Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy
D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D007155:Immunologic Factors